A combination of HER2-targeted drug and endocrine therapy was conceptually feasible to optimize neoadjuvant therapy in patients with HR-positive, HER2-positive breast cancer because of the crosstalk between the ER and HER2 signaling. This evidence concerns the gene ESR1 and breast carcinoma.